Literature DB >> 20461384

A case of primary Sjögren's syndrome complicated with inflammatory myopathy and interstitial lung disease.

Tomohiro Koga1, Yukiko Kouhisa, Hideki Nakamura, Akinari Mizokami, Masakatsu Motomura, Atsushi Kawakami, Katsumi Eguchi.   

Abstract

We experienced a case of a 63-year-old woman with primary Sjögren's syndrome (pSS) complicated with inflammatory myopathy and interstitial lung disease (ILD). She had suffered from morning stiffness and dry mouth for 1 year without being medically examined. A chest CT scan demonstrated ground glass opacity and a reticular shadow in the lower lung field. A diagnosis of SS was made based on positive findings from Schirmer's test, sialography of the parotid gland, a labial salivary gland biopsy and the presence of anti-SS-A antibody. Musculoskeletal symptoms were absent; however, the elevation of creatine kinase (CK) as well as magnetic resonance imaging (MRI)-proven inflammatory change of bilateral muscles of the thigh was evident. Histological examination of the thigh revealed diameter variation, degeneration of muscle fibers and inflammatory cell infiltration in the perivascular area, corresponding to the inflammatory myopathy of pSS. Oral prednisolone 30 mg/day was introduced, and serum CK rapidly decreased within 2 weeks. ILD also responded well to prednisolone without relapse. These clinical outcomes are consistent with extraglandular organ involvement of pSS.

Entities:  

Mesh:

Year:  2010        PMID: 20461384     DOI: 10.1007/s00296-010-1517-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  11 in total

Review 1.  Polymyositis and dermatomyositis (second of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-20       Impact factor: 91.245

Review 2.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 3.  SJOEGREN'S SYNDROME. A CLINICAL, PATHOLOGICAL, AND SEROLOGICAL STUDY OF SIXTY-TWO CASES.

Authors:  K J BLOCH; W W BUCHANAN; M J WOHL; J J BUNIM
Journal:  Medicine (Baltimore)       Date:  1965-05       Impact factor: 1.889

4.  A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long-term study.

Authors:  K Asmussen; V Andersen; G Bendixen; M Schiødt; P Oxholm
Journal:  J Intern Med       Date:  1996-06       Impact factor: 8.989

5.  Myositis in primary Sjögren's syndrome: clinical and pathological report.

Authors:  A Aoki; S Ono; A Ueda; E Hagiwara; T Tsuji; M Misumi; H Ideguchi; Y Takeda; Y Ishigatsubo
Journal:  Mod Rheumatol       Date:  2003-03       Impact factor: 3.023

6.  Subclinical myositis is common in primary Sjögren's syndrome and is not related to muscle pain.

Authors:  Bjorn Lindvall; Ann Bengtsson; Jan Ernerudh; Per Eriksson
Journal:  J Rheumatol       Date:  2002-04       Impact factor: 4.666

Review 7.  Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants.

Authors:  Kazuki Takada; Kenji Nagasaka; Nobuyuki Miyasaka
Journal:  Autoimmunity       Date:  2005-08       Impact factor: 2.815

Review 8.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

Review 9.  Myositis in primary Sjögren's syndrome. Report of 3 cases.

Authors:  A Kraus; M Cifuentes; A R Villa; J Jakez; E Reyes; D Alarcón-Segovia
Journal:  J Rheumatol       Date:  1994-04       Impact factor: 4.666

10.  Lung involvement in Sjögren's syndrome: a comparison between patients with primary and with secondary syndrome.

Authors:  C Vitali; A Tavoni; G Viegi; E Begliomini; A Agnesi; S Bombardieri
Journal:  Ann Rheum Dis       Date:  1985-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.